

Appendix 4: NEW JERSEY POPULATION AND INPATIENT HOSPITAL VOLUME PROJECTIONS – ADDITIONAL INFORMATION

In this Appendix, population projections are provided for New Jersey at the State level and at the individual market area level. Inpatient volume projections are also provided at the individual market level.

Figure 1 below compares New Jersey’s 2005 population and population projections for 2010 and 2015 by age

composition to the U.S. as a whole. The Figure illustrates that New Jersey’s proportion of population age 18 to 44 is projected to be slightly smaller and its population age 45 to 64 slightly larger than the nation as a whole in 2015.

Figure 1
New Jersey and U.S. Population Age Composition
(2005 and Projected 2010 and 2015)




Figure 2 on the following page shows that there is variation in the 2005 and projected 2015 population age composition across the eight New Jersey market areas. In 2005, the Toms River and Atlantic City areas had the highest proportions of population in the 65 and over age group. By 2015, the 65 and over age group is projected to comprise 19 percent of the Toms River area’s and 16 percent of the Atlantic City area’s and Hackensack, Ridgewood and Paterson areas’ total population.

As described in Chapter 4, to remove the effect of age composition and mix of services variations across market areas, we compared use rates and ALOS across market areas for 10 high volume DRGs for the 45 to 64 age group. Exhibits 1 and 2 illustrate the variation in use rates and ALOS for the 10 high volume DRGs across the eight market areas.

Figure 2
Age Composition of Population by Market Area (2005, and Projected 2010 and 2015)




Exhibit 1
Use Rate (Discharge per 1,000 Population) in 10 High Volume DRGs for New Jersey Residents' Age 45 - 64 by Market Area of Residence (2005)

DRG	Description	Atlantic City	Camden	Hackensack, Ridge, and Paterson	Morristown	New Brunswick	Newark	Toms River	Trenton	Entire State
14	Stroke with Infarction	1.10	0.99	0.79	0.49	0.76	1.35	0.81	1.33	0.91
88	Chronic Obstructive Pulmonary Disease	2.91	2.51	1.72	1.29	1.34	3.01	2.22	3.28	2.14
89	Simple Pneumonia and Pleurisy Age above 17 with Complications and Comorbidities	2.11	1.62	1.26	1.28	1.21	2.03	1.41	2.21	1.55
541	Respiratory Disorder Except Infections, Bronchitis, Asthma with Major Complications and Comorbidities	1.71	1.15	0.84	0.79	0.89	1.51	1.50	1.19	1.16
127	Heart Failure and Shock	2.32	1.80	1.39	0.90	1.01	4.42	1.49	3.13	1.98
143	Chest Pain	7.79	8.07	4.40	3.78	4.66	6.98	4.90	6.46	5.68
544	Congestive Heart Failure and Cardiac Arrhythmia with Major Complications and Comorbidities	1.10	0.58	0.49	0.30	0.55	1.45	0.77	0.95	0.74
854	Percutaneous Cardiovascular Procedure with Drug-Eluting Stent without Acute Myocardial Infarction	2.13	2.12	2.47	2.09	2.63	3.33	2.91	1.82	2.54
359	Uterine and Adnexa Procedures for Cancer In situ and Non-Malignancy without Complications and Comorbidities	3.86	3.53	3.37	3.53	3.80	4.25	3.76	3.99	3.73
430	Psychoses	4.23	3.32	4.72	3.82	1.98	6.32	5.07	3.53	4.27

Exhibit 2
ALOS in 10 High Volume DRGs for New Jersey Residents' Age 45-64 by Market Area of Residence (2005)

DRG	Description	Atlantic City	Camden	Hackensack, Ridge, and Paterson	Morristown	New Brunswick	Newark	Toms River	Trenton	Entire State
14	Stroke with Infarction	5.4	4.9	5.6	5.2	5.6	5.5	4.6	5.6	5.3
88	Chronic Obstructive Pulmonary Disease	4.2	4.2	4.9	4.7	5.6	5.2	4.7	4.4	4.8
89	Simple Pneumonia and Pleurisy Age above 17 with Complications and Comorbidities	5.0	4.9	5.6	4.7	5.3	5.7	5.1	5.4	5.3
541	Respiratory Disorder Except Infections, Bronchitis, Asthma with Major Complications and Comorbidities	7.0	6.9	8.6	7.7	8.3	8.8	7.7	7.0	7.9
127	Heart Failure and Shock	4.4	4.1	5.1	4.3	4.7	5.0	4.4	4.6	4.7
143	Chest Pain	1.9	1.7	1.8	1.5	1.8	2.2	1.9	2.1	1.9
544	Congestive Heart Failure and Cardiac Arrhythmia with Major Complications and Comorbidities	7.4	7.3	8.4	7.3	10.5	8.6	8.1	8.6	8.3
854	Percutaneous Cardiovascular Procedure with Drug-Eluting Stent without Acute Myocardial Infarction	2.0	1.9	1.7	1.5	1.5	1.8	1.4	1.5	1.7
359	Uterine and Adnexa Procedures for Cancer In situ and Non-Malignancy without Complications and Comorbidities	2.3	2.2	2.4	2.2	2.2	2.4	2.1	2.2	2.3
430	Psychoses	6.7	8.0	12.5	8.9	9.1	10.4	8.8	10.0	9.8

Figure 3 illustrates 2005 use rates compared to projected 2010 and 2015 use rates under the two projection scenarios.

Figure 3
Use Rates for New Jersey Residents by Market Area
(2005 and projected 2010 and 2015)

